CUSIP No. 185063 10 4
Page 15 of 20
This Amendment No. 4 on Schedule 13D amends the statement on Schedule 13D, dated June 7, 2016, which relates to the Common Stock, par value $0.001 per share (the “Common Stock”) of Clearside Biomedical, Inc. (the “Issuer”) which was previously amended on Schedule 13D/A, dated January 20 and April 17, 2017 and March 21, 2018 filed by:
Hatteras Venture Advisors III, LLC (“HVA III”)
Hatteras Venture Partners III, LP (“HVP III”)
Hatteras Venture Affiliates III, LP (“HV Affiliates”)
Hatteras Venture Advisors IV SBIC, LLC (“HVA SBIC”)
Hatteras Venture Partners IV SBIC, LP (“HVP SBIC”)
Hatteras Venture Advisors IV, LLC (“HVA IV”)
Hatteras Venture Partners IV, LP (“HVP IV”)
Hatteras NC Fund, LP (“Hatteras Fund”)
John C. Crumpler
Robert A. Ingram
Kenneth B. Lee
Clay B. Thorp
Douglas Reed
(collectively, the “Reporting Persons”).
Except as expressly amended below, the Schedule 13D, dated June 7, 2016, remains in effect.
Item 5. | Interest in Securities of the Issuer. |
| (a) | Aggregate number and percentage beneficially owned: |
HVA III — 1,429,518 or 3.8%
HVP III — 1,322,239 or 3.5%
HV Affiliates — 107,279 or less than 1%
HVA SBIC— 1,716,838 or 4.6%
HVP SBIC — 1,716,838 or 4.6%
HVA IV— 320,038 or less than 1%
HVP IV — 217,078 or less than 1%
Hatteras Fund— 102,960 or less than 1%
John C. Crumpler — 3,466,394 or 9.2%
Robert A. Ingram — 3,466,394 or 9.2%
Kenneth B. Lee — 3,466,394 or 9.2%
Clay B. Thorp — 3,485,644 or 9.3%
Douglas Reed — 3,466,394 or 9.2%
| (b) | Number of shares as to which the person has: |
| (i) | Sole power to vote or to direct the vote |
HVA III — 0
HVP III — 0
HV Affiliates — 0
HVA SBIC— 0
HVP SBIC — 0